Developments in functional, structural, and neurochemical imaging could help predict individuals with acute pain who are likely to progress to chronic pain.
Pain is the one concern that more often than not prompts people to see a health-care provider, so adequately addressing these complaints can significantly influence the relationship you have with your patients.
Perioperative use of etoricoxib, a selective COX-2 inhibitor, in patients undergoing total abdominal hysterectomy significantly reduces both resting and elicited pain and opioid (morphine) consumption compared with placebo.
Tanezumab, a monoclonal antibody that inhibits nerve growth factor, is efficacious in treating osteoarthritis pain and may provide greater symptomatic improvement compared with placebo and naproxen.
The MoxDuo combination of morphine and oxycodone may have a superior respiratory safety profile to that of equianalgesic morphine equivalent doses (MED) of either morphine or oxycodone alone.